Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 6, 2014, Pages 676-685

  Stepanova, M ^a   Nader, F ^a   Cure, S ^b,c   Bourhis, F ^b,c   Hunt, S ^a,d   Younossi, Z M ^a,d  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b OPTUM   (United States)

^c OptumInsight   (France)

^d Betty and Guy Beatty Center for Integrated Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PLACEBO; RIBAVIRIN; SOFOSBUVIR;

ADULT; ANEMIA; ANXIETY DISORDER; ARTICLE; ATTITUDE TO HEALTH; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EQ 5D SCORE; FATIGUE; FEMALE; HEALTH STATUS; HEPATITIS C; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SF 6D SCORE; TREATMENT DURATION;

ADOLESCENT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SURVEYS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; PATIENT PREFERENCE; QUALITY OF LIFE; QUESTIONNAIRES; RIBAVIRIN; URIDINE MONOPHOSPHATE;

EID: 84906281539     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12880     Document Type: Article

References (39)

1. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB,. Growth and quality of the cost-utility literature, 1976-2001. Value Health 2005; 8: 3-9.
2. Siegel JE, Weinstein MC, Russell LB, Gold MR,. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1339-41.
3. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC,. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1172-7.
4. van den Hout WB, Bremander A, Vliet Vlieland TP,. Recommendations for economic evaluations of non-pharmacological arthritis care: results from the CARE VI meeting 2010. Musculoskelet Care 2011; 9: 120-3.
5. Wright DR, Wittenberg E, Swan JS, Miksad RA, Prosser LA,. Methods for measuring temporary health states for cost-utility analyses. Pharmacoeconomics 2009; 27: 713-23.
6. Brown MM, Brown GC,. Update on value-based medicine. Curr Opin Ophthalmol 2013; 24: 183-9.
7. Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH,. Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res (Hoboken) 2011; 63 (Suppl. 11): S383-412.
8. Kharroubi SA, Brazier JE, Roberts J, O'Hagan A,. Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ 2007; 26: 597-612.
9. Dan AA, Kallman JB, Srivastava R, Younoszai Z, Kim A, Younossi ZM,. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl 2008; 14: 321-6.
10. Dolan P,. Modelling valuations in EuroQol health states. Med Care 1997; 35: 1095-108.
11. Wolowacz S, Petrillo J, Doward L, Briggs A,. Measuring Utility for Economic Models Within Clinical Trials: Can we do Better? ISPOR 16th Annual European Congress, Issue Panel 3, 2013 Ireland, Dublin.
12. Ara R, Brazier J,. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a Mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008; 11: 1131-43.
13. Richardson J, Khan MA, Iezzi A, Maxwell A,. Cross-national comparison of twelve quality of life instruments: MIC paper 3 United Kingdom. November, 2012. Clayton, Vic., Australia: Centre for Health Economics, Monash University.
14. Rowen D, Brazier J, Tsuchiya A, Alava MH,. Valuing states from multiple measures on the same visual analogue scale: a feasibility study. Health Econ 2012; 21: 715-29.
15. Gray A, Clarke P, Rivero-Arias O,. Estimating the association between SF-36 responses and EQ-5D utility values by direct mapping. Proceedings of Health Economists Study Group Meeting (HESG) (January 2004, Paris, France), paper H8, 2004, pp. 1-18.
16. Rowen D, Brazier J, Roberts J,. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes 2009; 31: 27.
17. Hajarizadeh B, Grebely J, Dore GJ,. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-62.
18. Mathis AS,. Economic burden and current managed care challenges associated with hepatitis C. Am J Manag Care 2012; 18 (14 Suppl.): S350-9.
19. Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH,. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care 2011; 17: 657-64.
20. Camma C, Petta S, Cabibbo G, et al,. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol 2013; 59: 658-66.
21. Chan K, Lai MN, Groessl EJ, et al,. Cost-effectiveness analysis of direct-acting antiviral therapy for treatment-naive patients with chronic hepatitis C genotype 1 infection in the Veterans health administration. Clin Gastroenterol Hepatol. 2013; 11: 1503-10.
22. Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M,. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. Transpl Int 2013; 26: 527-34.
23. Hadziyannis SJ, Sette H Jr, Morgan TR, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
24. Marcellin P, Chousterman M, Fontanges T, et al,. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int 2011; 31: 516-24.
25. McHutchison JG, Manns MP, Muir AJ, et al,. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
26. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
27. Gao X, Stephens JM, Carter JA, Haider S, Rustgi VK,. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 335-43.
28. Vera-Llonch M, Martin M, Aggarwal J, et al,. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 2013; 38: 124-33.
29. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
30. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
31. Younossi ZM, Stepanova M, Mir HM, et al,. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2013; 58: S557.
32. Younossi ZM, Stepanova M, Henry L, et al,. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013. doi:pii: S1542-3565(13)01838-7. doi: 10.1016/j.cgh.2013.11.032
33. Miller MH, Agarwal K, Austin A, et al,. Review article: 2014 UK consensus guidelines-hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 2014. doi: 10.1111/apt.12764
34. Koff RS,. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 478-87. doi: 10.1111/apt.12601
35. Walters SJ, Brazier JE,. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003; 11: 4.
36. Younossi ZM, Stepanova M, Zeuzem S, et al,. Patient-reported outcomes assessment in chronic hepatitis c treated with sofosbuvir and ribavirin: the VALENCE Study. J Hepatol 2014. pii: S0168-8278(14)00220-7. doi: 10.1016/j.jhep.2014.04.003
37. Younossi ZM, Stepanova M, Nader F, et al,. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014 59: 2161-9.
38. Hsu PC, Federico CA, Krajden M, et al,. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2012; 27: 149-57.
39. Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A,. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat 2013; 20: 550-5.